Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma

N Engl J Med. 2024 Nov 28;391(21):2061-2062. doi: 10.1056/NEJMc2411843.

Authors

Hussam Alkaissi¹, Karel Pacak¹, Jared Rosenblum¹

Affiliation

¹ National Institutes of Health, Bethesda, MD [email protected].

PMID: 39602644
DOI: 10.1056/NEJMc2411843

No abstract available

Publication types

Letter
Comment